BioWorld

June 27, 2008

View Archived Issues

Vanda Improves Sleep Onset in Phase III Insomnia Trial

Shares of Vanda Pharmaceuticals Inc. rose and then fell on Thursday as investors tried to digest top-line data from the company's Phase III trial of tasimelteon (VEC-162) in chronic insomnia. (BioWorld Today) Read More

FOBs Could Save U.S. $25B Over 10 Years

Read More

Novel Calcium Channel Found, Linked to Risk of Alzheimer's

Read More

Sequenom's Offering Adds $85M for its Diagnostic Development

Read More

Other News To Note

Read More

Clinic Roundup

Read More